改善美国心力衰竭治疗药物研发:心力衰竭协作组织
本文总结2017年3月多利益相关方会议,讨论美国心衰临床试验环境面临的复杂性、成本、监管要求等挑战,提出可操作建议,包括成立有组织的心力衰竭协作组织,以提高试验效率并加速有效疗法研发。
要点
- 多利益相关方会议提出成立心力衰竭协作组织以改善试验效率。
- 当前心衰临床试验环境受复杂性、成本及监管要求等制约。
- 建议聚焦可操作机会以加速有效心衰疗法的研发。
核心结论
- 建议成立有组织的心力衰竭协作组织,以改善临床试验效率并加速有效心衰疗法研发。
研究设计与样本
- 2017年3月召开的多利益相关方会议,参与者包括患者、研究者、学术领袖、制药与器械行业代表、学会代表、第三方支付方及FDA、NIH、CMS政府代表。
主要发现
- 当前心衰临床试验环境因复杂性增加、成本上升、监管要求、利益相关方竞争性需求、实施挑战及患者与研究者参与度下降而承压。
临床怎么用
- 通过多利益相关方协作组织推动心衰临床试验效率提升和疗法研发加速。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The current heart failure clinical trial environment is strained by increasing complexity and cost, regulatory requirements, competing demands on stakeholders, implementation challenges, and decreasing patient and investigator participation. To begin the process of developing potentially effective strategies and tactics, stakeholders including patients; investigators; academic leaders; pharmaceutical and device industry representatives; society representatives; third-party payers; and government representatives from the U.S. Food and Drug Administration, National Institutes of Health, and Centers for Medicare and Medicaid Services convened in March of 2017. This paper summarizes the discussions, outlines current challenges and actionable opportunities, and makes targeted recommendations to achieve the goals of improving efficiency in clinical trials and speeding the development of effective heart failure therapies, including the formation of an organized Heart Failure Collaboratory.
引用
- O'Connor CM, Psotka MA, Fiuzat M, et al. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. J Am Coll Cardiol. 2018. PMID: 29389362. doi:10.1016/j.jacc.2017.11.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。